Indaptus Therapeutics

Indaptus Therapeutics, Inc. is a pre-clinical biotechnology company. It engages in the development of a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. The firm created patented treatment methods and associated patented compositions for attenuation and killing of non-pathogenic, Gram-negative bacteria. The company was founded by Michael James Newman on February 24, 2021 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Preclinical data demonstrates Decoy platform single agent anti-tumor activity and combination-mediated tumor eradication with NSAID, anti-PD1 checkpoint therapy, low dose chemotherapy (LDC) and/or targeted antibody therapy Preclinical data demonstrates Decoy platform single agent anti-tumor activity and combination-mediated tumor eradication with NSAID, anti-PD1 checkpoint therapy, low dose chemotherapy (LDC) and/or targeted antibody therapy

Indaptus Therapeutics' Pioneering Research on Novel Immunotherapy Approach Published in Peer-Reviewed Frontiers in Immunology

NEW YORK, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, announces compelling safety, pharmacokinetics, and biomarker data on its lead compound, Decoy20, at the Society for Immunotherapy of Cancer (SITC) 2024 annual meeting. The data derive from two cohorts (13 patients) of Decoy20 single administration and one cohort (6 patients) of Decoy20 weekly administration in the Company's ongoing Phase 1 clinical trial.

Indaptus Therapeutics Presents Encouraging Interim Safety Data from Phase 1 Clinical Trial of Decoy20 at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting

NEW YORK, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) announced today that Jeffrey A. Meckler, Chief Executive Officer, will present at two upcoming investor conferences:

Indaptus Therapeutics to Present at Two Upcoming Investor Conferences

Company to present poster at American Society of Clinical Oncology (ASCO) Annual Meeting on June 1, 2024 highlighting initial results from its Phase 1 clinical trial of Decoy20 Company to present poster at American Society of Clinical Oncology (ASCO) Annual Meeting on June 1, 2024 highlighting initial results from its Phase 1 clinical trial of Decoy20

Indaptus Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

Results Indicate Decoy Platform Broadly Boosts Immune System's Ability to Fight Tumors Directly and Indirectly Results Indicate Decoy Platform Broadly Boosts Immune System's Ability to Fight Tumors Directly and Indirectly

Indaptus Therapeutics Presents Positive Mechanism of Action Data at the American Association for Cancer Research Annual Meeting

Data demonstrates that Company's Decoy platform successfully induces or activates multiple immune cell types involved in anti-tumor responses

Indaptus Therapeutics Previews Positive Mechanism of Action Data to be Presented at the American Association for Cancer Research Annual Meeting

NEW YORK, March 13, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”) today announced financial results for the fourth quarter and fiscal year ended December 31, 2023 and provided a corporate update.

Indaptus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update

• Positive data following completion of second cohort of Phase 1 trial of Decoy 20 leads independent Safety Review Committee to recommend initiating multi-dosing cohort

Indaptus Therapeutics Announces Positive Results from Second Cohort of Phase 1 Trial; Company Initiates Multi-Dose Cohort

NEW YORK, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, is pleased to announce the launch of a new social media initiative to provide education and updates about the company. Recognizing the importance of engaging with all stakeholders, Indaptus will generate content on a variety of digital platforms, including X (formerly known as Twitter) and LinkedIn.

Indaptus Therapeutics Expands Digital Presence with Launch of Social Media Channels

Patent will provide additional protection covering a composition targeting any viral infection, including hepatitis B, HIV, and influenza Patent will provide additional protection covering a composition targeting any viral infection, including hepatitis B, HIV, and influenza

European Patent Office Approves Key Patent for Indaptus Therapeutics' Platform Technology

NEW YORK, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”) today announced financial results for the third quarter ended September 30, 2023 and provided a corporate update.

Indaptus Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Poster to be presented at 38 th Annual Meeting of the Society for Immunotherapy of Cancer on November 4 , 2023

Indaptus Therapeutics to Present Positive Pharmacodynamic (PD) Immune and Pharmacokinetic (PK) Results with Patients from First Cohort of Ongoing Phase 1 Study of Decoy20 at Cancer Immunotherapy Meeting

NEW YORK, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (NASDAQ: INDP) announces that Indaptus' CEO, Jeffrey Meckler will present at Tribe Public's Webinar Presentation and Q&A Event titled “Immunotherapy Reimagined.

Registration Is Now Open For Tribe Public's Webinar Event "Immunotherapy Reimagined" Featuring Indaptus Therapeutics' CEO On Friday, September 29, 2023

NEW YORK, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) announced today that Jeffrey A. Meckler, Chief Executive Officer, will present a corporate overview at the H.C. Wainwright 25th Annual Global Investment Conference. The conference is being held on September 11 – 13, 2023 at the Lotte New York Palace Hotel.

Indaptus Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference

NEW YORK, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”) today announced financial results for the second quarter ended June 30, 2023 and provided a corporate update.

Indaptus Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update

NEW YORK, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”) today announced completion of the first cohort of patients who received a single dose in Part 1 of its INDP-D101 trial of Decoy20 and the initiation of a new cohort following review of data by the Safety Review Committee as prescribed by the clinical trial protocol.

Indaptus Therapeutics Announces Opening of Next Cohort in Single Dose Ranging Study of Decoy20

NEW YORK, Aug. 07, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a biotechnology company focused on discovering and developing transformative therapeutics for patients, announces the appointment of Roger Waltzman, M.D. as its Chief Medical Officer, effective August 7, 2023.

Indaptus Therapeutics Appoints Industry Veteran Roger Waltzman, M.D. Chief Medical Officer

Enrollment Continues for Phase 1 Clinical Trial of Decoy20 for Treatment of Solid Tumors with First Patient Dosed In March 2023 Enrollment Continues for Phase 1 Clinical Trial of Decoy20 for Treatment of Solid Tumors with First Patient Dosed In March 2023

Indaptus Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update

NEW YORK, May 09, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announces that it has received notice of allowance for a disease agnostic, composition and method of preparing patent (#429419) from Intellectual Property India for its Decoy immunotherapy platform. India marks the 32nd country in which Indaptus holds patents for its Decoy immunotherapy platform.

Following Granting of Indian Patent, Indaptus Therapeutics Achieves Patent Protection in 32 Countries for Decoy Immunotherapy Platform

Dr. Newman also to give two presentations on the Company's Decoy platform at the event to be held in Boston May 9-11, 2023 Dr. Newman also to give two presentations on the Company's Decoy platform at the event to be held in Boston May 9-11, 2023

Indaptus Therapeutics' Chief Scientific Officer Michael Newman, Ph.D. Named a Chair of the 4th STING & TLR-Targeting Therapies Summit

NEW YORK, April 20, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announces that CEO Jeffrey A. Meckler will present a corporate overview at the Planet MicroCap Showcase: VEGAS 2023. The conference is being held on April 25 – 27, 2023 at the Horseshoe Hotel & Casino (formerly Bally's) in Las Vegas, NV.

Indaptus Therapeutics to Present at the Planet MicroCap Showcase: VEGAS 2023

Indaptus (INDP) announces positive pre-clinical efficacy data from a poster presentation made at a scientific conference from its proprietary Decoy platform pre-clinical study. Stock is up 22%.

Indaptus (INDP) Surges on Upbeat Pre-Clinical Decoy Data

Data presented were crucial to initiating its ongoing Phase 1 clinical trial with Decoy 20 in solid tumors Data presented were crucial to initiating its ongoing Phase 1 clinical trial with Decoy 20 in solid tumors

UPDATE -- Indaptus Therapeutics Presents Data Demonstrating Preclinical Efficacy of Decoy, its Bacteria-Based Immunotherapy Platform Technology, at the American Association for Cancer Research Conference 2023

Indaptus Therapeutics Presents Data Demonstrating Preclinical Efficacy of Decoy, its Bacteria-Based Immunotherapy Platform Technology, at the American Association for Cancer Research Conference 2023

NEW YORK, March 22, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announces that it will participate at the Investor Summit Conference being held virtually on March 29, 2023.

News for Indaptus Therapeutics Stock (INDP)